上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
CAY10471 Racemate (Synonyms: TM30089 Racemate) 纯度: 99.35%
CAY10471 Racemate (TM30089 Racemate) 是一种有效、高度选择性的前列腺素 D2 受体 (CRTH2) 拮抗剂,对 hCRTH2 的 Ki 值为 0.6 nM,对其选择性远高于人血栓素 A2 受体 TP (Ki,>10000 nM) 或 PGD2 受体 DP (Ki,1200 nM)。CAY10471 Racemate 对小鼠和大鼠的同源 CRTH2 也具有拮抗作用。
CAY10471 Racemate Chemical Structure
CAS No. : 844639-57-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥1210 | In-stock | |
5 mg | ¥1100 | In-stock | |
10 mg | ¥1800 | In-stock | |
25 mg | ¥3900 | In-stock | |
50 mg | 询价 | ||
100 mg | 询价 |
* Please select Quantity before adding items.
CAY10471 Racemate 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- GPCR/G Protein Compound Library
- Immunology/Inflammation Compound Library
- Anti-Cancer Compound Library
- Endocrinology Compound Library
- Angiogenesis Related Compound Library
生物活性 |
CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective prostaglandin D2 receptor CRTH2 antagonist, with a Ki of 0.6 nM for hCRTH2, selective over human thromboxane A2 receptor TP (Ki, >10000 nM) or PGD2 receptor DP (Ki, 1200 nM). CAY10471 Racemate also has effect on mouse and rat orthologs of CRTH2[1]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
CAY10471 Racemate (Compound 13) inhibits PGD2-induced inositol phosphate or cAMP formation, suppresses β-arrestin translocation with IC50s of 12 and 3 nM, respectively[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
416.47 |
||||||||||||||||
Formula |
C21H21FN2O4S |
||||||||||||||||
CAS 号 |
844639-57-2 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 150 mg/mL (360.17 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务